In utero exposure to levetiracetam vs valproate

Objective: To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy. Methods: The children, aged between 36 and 54 months, were recruited from the United Kingdom and assessed using the Griffiths Mental Development Scales and the Reynell Language Development Scale. Maternal demographic and epilepsy information was also collected for use in statistical regression. This is an observational study with researchers not involved in the clinical management of the mothers enrolled. Results: After controlling for confounding variables, children exposed to LEV in utero (n = 53) did not differ from unexposed control children (n = 131) on any scale administered. Children exposed to VPA (n = 44) in utero scored, on average, 15.8 points below children exposed to LEV on measures of gross motor skills (95% confidence interval [CI] −24.5 to −7.1, p < 0.001), 6.4 points below on comprehension language abilities (95% CI −11.0 to −1.8, p = 0.005), and 9.5 points below on expressive language abilities (95% CI −14.7 to −4.4, p < 0.001). Conclusion: The current study indicates that children exposed to LEV in utero were superior in their language and motor development in comparison to children exposed to VPA. This information should be used collaboratively between health care professionals and WWE when deciding on women's preferred choice of antiepileptic drug.

[1]  G. Koren,et al.  Dose-Dependent Risk of Malformations With Antiepileptic Drugs: An Analysis of Data From the EURAP Epilepsy and Pregnancy Registry , 2015, Therapeutic drug monitoring.

[2]  H. Scharfman,et al.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research , 2013, Epilepsy & Behavior.

[3]  K. Meador,et al.  Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study , 2013, The Lancet Neurology.

[4]  N. Delanty,et al.  Levetiracetam in pregnancy , 2013, Neurology.

[5]  W. Hauser,et al.  Comparative safety of antiepileptic drugs during pregnancy , 2012, Neurology.

[6]  T. Tomson,et al.  Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry , 2011, The Lancet Neurology.

[7]  J. Morrow,et al.  Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine , 2011, Archives of Disease in Childhood.

[8]  A. Wood,et al.  Language skills of school-aged children prenatally exposed to antiepileptic drugs , 2011, Neurology.

[9]  G. Baker,et al.  Child development following in utero exposure , 2011, Neurology.

[10]  G. Baker,et al.  Early cognitive development in children born to women with epilepsy: A prospective report , 2010, Epilepsia.

[11]  D. Baş,et al.  Effect of prenatal levetiracetam exposure on motor and cognitive functions of rat offspring , 2010, Brain and Development.

[12]  T. O'Brien,et al.  Changing patterns of antiepileptic drug use in pregnant Australian women , 2010, Acta neurologica Scandinavica.

[13]  W. Hauser,et al.  Management issues for women with epilepsy—Focus on pregnancy (an evidence‐based review): II. Teratogenesis and perinatal outcomes , 2009, Epilepsia.

[14]  F. Besag,et al.  Changing trends in antiepileptic drug prescribing in girls of child-bearing potential , 2009, Archives of Disease in Childhood.

[15]  Sanjeev V Thomas,et al.  Motor and mental development of infants exposed to antiepileptic drugs in utero , 2008, Epilepsy & Behavior.

[16]  M. Barreto,et al.  Determinants of early cognitive development: hierarchical analysis of a longitudinal study. , 2008, Cadernos de saude publica.

[17]  Jinsook Kim,et al.  Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus Polytherapy , 2007, Journal of Pharmacology and Experimental Therapeutics.

[18]  E. Gaily,et al.  Neuropsychological outcomes in children of mothers with epilepsy , 2007, Journal of the International Neuropsychological Society.

[19]  A. Kaindl,et al.  Sulthiame but not levetiracetam exerts neurotoxic effect in the developing rat brain , 2005, Experimental Neurology.

[20]  B. Irwin,et al.  U.K. Epilepsy and Pregnancy Group , 2004, Epilepsia.

[21]  J. Clayton-Smith,et al.  A note on Pierre Marie (1853–1940) , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  J. Wooldridge.  Inverse probability weighted estimation for general missing data problems , 2004 .

[23]  R. Finnell,et al.  Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity , 2003, Epilepsia.

[24]  J. Olney,et al.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  松岡 恵子,et al.  日本語版National Adult Reading Test(JART)の作成 , 2002 .

[26]  Nicola Brace,et al.  SPSS for psychologists , 1999 .

[27]  R. Lynn.  What has caused the Flynn effect? Secular increases in the Development Quotients of infants , 2009 .

[28]  O. P. Gray,et al.  Griffiths Scales of Mental Development and different users. , 1980, Child: care, health and development.